Back

Biofrontera says FDA approves Ameluz red-light PDT for superficial basal cell carcinoma

Verifying
  • Biofrontera announced FDA approval of Ameluz for superficial basal cell carcinoma.
  • Ameluz is approved as a red-light photodynamic therapy treatment.
  • The approval applies specifically to superficial basal cell carcinoma.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.